{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:02:58Z","timestamp":1791864178360,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.lungcan.2023.107318","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:20:44Z","timestamp":1690946444000},"page":"107318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-0326","authenticated-orcid":false,"given":"Remei","family":"Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Loutfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Olaverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107318_b0005","doi-asserted-by":"crossref","unstructured":"D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, S. Peters, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 29 (2018) iv192\u2013iv237. doi: 10.1093\/annonc\/mdy275.","DOI":"10.1093\/annonc\/mdy275"},{"key":"10.1016\/j.lungcan.2023.107318_b0010","doi-asserted-by":"crossref","unstructured":"F. Casaluce, A. Sgambato, P. Maione, A. Spagnuolo, C. Gridelli, Lung cancer, elderly and immune checkpoint inhibitors, J. Thorac. Dis. 10 (2018) S1474\u2013S1481. doi: 10.21037\/jtd.2018.05.90.","DOI":"10.21037\/jtd.2018.05.90"},{"key":"10.1016\/j.lungcan.2023.107318_b0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/annonc\/mdu268","article-title":"A review of the management of elderly patients with non-small-cell lung cancer","volume":"26","author":"Blanco","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0020","doi-asserted-by":"crossref","unstructured":"R.A.N. Johnpulle, R.M. Conry, J.A. Sosman, I. Puzanov, D.B. Johnson, Responses to immune checkpoint inhibitors in nonagenarians, Oncoimmunology. 5 (2016) e1234572. doi: 10.1080\/2162402X.2016.1234572.","DOI":"10.1080\/2162402X.2016.1234572"},{"key":"10.1016\/j.lungcan.2023.107318_b0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14740338.2020.1736554","article-title":"The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer","volume":"19","author":"Mazarico Gallego","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.lungcan.2023.107318_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4321\/S1886-36552014000400007","article-title":"Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy","volume":"12","author":"Singh","year":"2014","journal-title":"Pharm. Pract. (Granada)."},{"key":"10.1016\/j.lungcan.2023.107318_b0035","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","article-title":"Redefining the elderly as aged 75 years and older: Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.lungcan.2023.107318_b0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107318_b0045","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1\u2013Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107318_b0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107318_b0055","doi-asserted-by":"crossref","unstructured":"T.S.K. Mok, Y. Wu, I. Kudaba, D.M. Kowalski, B.C. Cho, H.Z. Turna, G.C. Jr, V. Srimuninnimit, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised , open-label, controlled, phase 3 trial, Lancet. 393 (2019) 1819\u20131830. doi: 10.1016\/S0140-6736(18)32409-7.","DOI":"10.1016\/S0140-6736(18)32409-7"},{"issue":"10027","key":"10.1016\/j.lungcan.2023.107318_b0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107318_b0065","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107318_b0070","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/annonc\/mdq687","article-title":"EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors","volume":"22","author":"Pallis","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jgo.2010.03.005","article-title":"Geriatric oncology research in the cooperative groups: A report of a SIOG special meeting","volume":"1","author":"Hurria","year":"2010","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0959-8049(01)00127-7","article-title":"Interpreting quality of life data: Population-based reference data for the EORTC QLQ-C30","volume":"37","author":"Fayers","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107318_b0090","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/bjc.2013.407","article-title":"International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer","volume":"109","author":"Wheelwright","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0095","doi-asserted-by":"crossref","unstructured":"P.J. Hollen, R.J. Gralla, M.G. Kris, L.M. Potanovich, Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS), Eur. J. Cancer. 29 (1993) S51\u2013S58. doi: 10.1016\/S0959-8049(05)80262-X.","DOI":"10.1016\/S0959-8049(05)80262-X"},{"key":"10.1016\/j.lungcan.2023.107318_b0100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lungcan.2023.107318_b0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bj.2020.07.009","article-title":"Immunotherapy in older patients with cancer","volume":"44","author":"Granier","year":"2021","journal-title":"Biomed. J."},{"key":"10.1016\/j.lungcan.2023.107318_b0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1\u2013positive advanced non\u2013small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835918763493","article-title":"PD-L1 expression testing in non-small cell lung cancer","volume":"10","author":"Teixid\u00f3","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0120","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00432-020-03252-4","article-title":"Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1\/PD-L1 antibody-based immunotherapy","volume":"146","author":"Hakozaki","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0125","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1\u2013Positive Advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107318_b0130","doi-asserted-by":"crossref","first-page":"109599","DOI":"10.1016\/j.celrep.2021.109599","article-title":"Evaluating the impact of age on immune checkpoint therapy biomarkers","volume":"36","author":"Erbe","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.lungcan.2023.107318_b0135","unstructured":"L. Dang, K.W. Gallo, S. Garaud, H. Duvillier, J.N. Lodewyckx, C. Solinas, P. Da Silvia, C. Gu, C. Sibille, D. Bron, Aging and PD-1 & PD-L1 Gene Expression: Markers of Immunosenescence? PB1774, in: Eur. Hematol. Assoc., 2016. https:\/\/library.ehaweb.org\/eha\/2016\/21st\/134674\/dominique.bron.aging.and.pd-1.26.pd-l1.gene.expression.markers.of.html."},{"key":"10.1016\/j.lungcan.2023.107318_b0140","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jcsm.12206","article-title":"Muscle mass and association to quality of life in non- small cell lung cancer patients","volume":"8","author":"Bye","year":"2017","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lungcan.2023.107318_b0145","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1186\/s12885-017-3795-2","article-title":"Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan : a prospective longitudinal observational study","volume":"17","author":"Naito","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0150","first-page":"1623","article-title":"Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with fi rst-line chemotherapy, Thorac","volume":"9","author":"Cortellini","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2019.06.007","article-title":"Muscle derangement and alteration of the nutritional machinery in NSCLC","volume":"141","author":"Trestini","year":"2019","journal-title":"Crit. Rev. Oncol. \/ Hematol."},{"key":"10.1016\/j.lungcan.2023.107318_b0160","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1080\/01635581.2022.2059093","article-title":"Prognostic Value of Pretreatment Geriatric Nutrition Risk Index in Lung Cancer Patients: A Meta-Analysis","volume":"74","author":"Wang","year":"2022","journal-title":"Nutr. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107318_b0165","doi-asserted-by":"crossref","first-page":"e000689","DOI":"10.1136\/esmoopen-2020-000689","article-title":"Evaluation of nutritional status in non-small cell lung cancer: screening, assessment and correlation with treatment outcome","volume":"5","author":"Trestini","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107318_b0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12885-021-07872-y","article-title":"Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer","volume":"21","author":"Ester","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0175","first-page":"2391","article-title":"Immunotherapy beyond progression in patients with advanced non-small cell lung cancer, Transl. Lung","volume":"9","author":"Ge","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107318_b0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lungcan.2023.107318_b0185","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2023.107318_b0190","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/imt-2018-0042","article-title":"Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature","volume":"10","author":"Rebuzzi","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lungcan.2023.107318_b0195","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-Carboplatin Alone or with Bevacizumab for Non\u2013Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107318_b0200","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0205","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","article-title":"End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer \u2013 Alliance for Clinical Trials in Oncology \u2013 International Society of Geriatric Oncology Position Article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0210","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2023.107318_b0215","doi-asserted-by":"crossref","unstructured":"S.-M. Lee, C. Schulz, K. Prabhash, D. Kowalski, A. Szczesna, B. Han, S. Peters, IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen, SSRN. (2022). doi: 10.2139\/ssrn.4307691.","DOI":"10.2139\/ssrn.4307691"},{"key":"10.1016\/j.lungcan.2023.107318_b0220","unstructured":"E. Quoix, C. Mascaux, Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY). NCT03977194, ClinicalTrials.Gov. (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03977194 (accessed November 16, 2022)."},{"key":"10.1016\/j.lungcan.2023.107318_b0225","unstructured":"A. Jatoi, Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer. NCT04533451, ClinicalTrials.Gov. (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04533451 (accessed November 16, 2022)."},{"key":"10.1016\/j.lungcan.2023.107318_b0230","unstructured":"M.C. Piccirillo, F. Perrone, A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5). NCT03975114, ClinicalTrials.Gov. (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03975114 (accessed November 16, 2022)."},{"key":"10.1016\/j.lungcan.2023.107318_b0235","unstructured":"J. Kuon, Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION). NCT03345810, ClinicalTrials.Gov. (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345810 (accessed November 16, 2022)."},{"key":"10.1016\/j.lungcan.2023.107318_b0240","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line Immunotherapy for Non\u2013Small-Cell Lung Cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107318_b0245","doi-asserted-by":"crossref","first-page":"101192","DOI":"10.1016\/j.esmoop.2023.101192","article-title":"Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)","volume":"8","author":"Gridelli","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107318_b0250","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0255","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of Immune Checkpoint Inhibitors in Elderly Patients : An Observational Study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lungcan.2023.107318_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients e the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107318_b0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti e programmed death (ligand) PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0275","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0280","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0285","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107318_b0290","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1200\/JCO.2005.02.527","article-title":"Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A Prognostic analysis of the multicenter italian lung cancer in the elderly s","volume":"23","author":"Maione","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0295","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jgo.2013.02.002","article-title":"Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer","volume":"4","author":"Wildes","year":"2013","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0300","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jgo.2019.05.021","article-title":"Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors","volume":"11","author":"Welaya","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107318_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/8886193","article-title":"Leisure and Productivity in Older Adults with Cancer: A Systematic Review","volume":"2021","author":"Engels","year":"2021","journal-title":"Occup. Ther. Int."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:48Z","timestamp":1759237548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":61,"alternative-id":["S0169500223008565"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107318","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107318"}}